Chemotherapy is not only for cancer. While most people associate it with cancer treatment, several chemotherapy drugs are routinely used to treat autoimmune diseases, blood disorders, neurological conditions, and other non-cancerous illnesses. The term “chemotherapy” was actually coined to describe drugs used against infectious diseases, and its meaning has always been broader than oncology alone.
The key difference is usually dosage. When chemotherapy drugs are used for non-cancer conditions, the doses tend to be dramatically lower, and the goal shifts from killing tumor cells to calming the immune system or correcting abnormal cell production.
How Chemotherapy Works Beyond Cancer
Chemotherapy drugs target cells that divide rapidly. In cancer, that’s exactly what you want: stop the fast-growing tumor cells from multiplying. But rapid cell division also plays a role in other diseases. In autoimmune conditions, immune cells multiply aggressively and attack healthy tissue. In certain blood disorders, the bone marrow churns out abnormal cells. Chemotherapy can slow or halt those processes too.
The drugs themselves are often identical to what an oncologist would prescribe. What changes is the dose, the schedule, and the intent. A cancer patient might receive a chemotherapy drug at very high doses to destroy as many malignant cells as possible. Someone with rheumatoid arthritis might take a tiny fraction of that same drug once a week to keep inflammation under control.
Autoimmune Diseases
Methotrexate is one of the most commonly prescribed medications for rheumatoid arthritis, and it was originally developed as a cancer drug. For leukemia, a single dose can be as high as 1,000 milligrams. For rheumatoid arthritis, the typical weekly dose is 15 to 25 milligrams, a fraction of the cancer dose. At that lower level, the drug works through a completely different mechanism. Rather than killing cells outright, it increases levels of a signaling molecule called adenosine, which triggers a cascade of anti-inflammatory effects throughout the body.
Lupus is another autoimmune disease frequently treated with chemotherapy drugs. When lupus attacks the kidneys (a serious complication called lupus nephritis), cyclophosphamide is considered a first-line treatment. The standard approach involves intravenous infusions once a month for about six months, combined with corticosteroids. A European trial across nine countries found that lower-dose regimens (given every two weeks instead of monthly) achieved similar remission rates while significantly reducing side effects like infections, menstrual disruption, and bone marrow suppression.
Rituximab, originally developed for lymphoma, is now widely used to treat ANCA-associated vasculitis, a condition where the immune system inflames and damages blood vessels. In real-world clinical data, 65% of patients achieved remission within about four months of starting treatment, and 96% of those on maintenance therapy achieved complete response.
Sickle Cell Disease
Hydroxyurea is classified as a chemotherapy drug, but for millions of people with sickle cell disease, it’s a daily medication that prevents pain crises and hospitalizations. It works by temporarily slowing blood cell production in the bone marrow. When production resumes, the body generates red blood cells containing higher levels of fetal hemoglobin, a form of hemoglobin that prevents the “sickling” process that causes so much pain and organ damage.
The clinical evidence behind this is strong. A major Phase III trial was stopped early by the National Heart, Lung, and Blood Institute because the benefit was so clear: patients on hydroxyurea had significantly fewer painful episodes compared to placebo, and waiting longer to report results would have meant withholding an effective treatment. In infants, hydroxyurea reduced painful events, cut the need for blood transfusions, and lowered hospitalization rates. It’s now considered the primary disease-modifying therapy for sickle cell anemia.
Multiple Sclerosis
Cladribine, a drug originally used in blood cancers, is now approved in the U.S. and Europe for relapsing-remitting multiple sclerosis. It works by selectively reducing certain immune cells that drive the disease. In a 96-week trial called CLARITY, cladribine cut the annual relapse rate by more than half compared to placebo (0.14 versus 0.33 relapses per year), reduced the risk of sustained disability progression by 33%, and decreased the number of new brain lesions by roughly 74 to 86% depending on the type measured.
What makes cladribine unusual among MS treatments is its dosing schedule. Patients take short courses of oral tablets over two years rather than ongoing daily or weekly medication, which appeals to people who want fewer disruptions to daily life.
Preparing for Stem Cell Transplants
Chemotherapy plays a critical role in stem cell transplants for non-cancerous diseases like sickle cell disease, severe aplastic anemia, and certain genetic disorders. Before a transplant, the patient’s bone marrow needs to be cleared out to make room for the donor’s healthy cells. This “conditioning” phase typically involves chemotherapy with alkylating agents, sometimes combined with radiation.
The conditioning step is necessary but comes with real costs. The drugs can damage healthy dividing cells throughout the body, which is an acceptable trade-off in cancer but harder to justify in non-malignant diseases where the patient may be young and otherwise stable. Conditions like Fanconi anemia, which involves defective DNA repair, make patients especially vulnerable to the toxic effects of standard conditioning drugs. This has pushed researchers toward gentler, less toxic conditioning approaches for non-cancer transplants.
Why the Doses Matter
If your doctor prescribes a drug that’s technically classified as chemotherapy for a non-cancer condition, the side effect profile is often very different from what cancer patients experience. Lower doses mean less suppression of healthy cells, which generally translates to milder nausea, less hair loss, and a lower risk of serious infections. That said, these drugs still carry real risks. Regular blood work is standard to monitor for drops in blood cell counts or signs of liver stress, and your treatment team will adjust doses accordingly.
The distinction worth remembering is that “chemotherapy” describes a category of drugs, not a single treatment or a single disease. The same molecule can serve very different purposes at different doses, and a prescription for methotrexate or hydroxyurea doesn’t mean you’re being treated for cancer.